Dabigartran etexilate mesylate is an oral anticoagulant which acts as direct thrombin inhibitor (factor II a) [1]. The drug is available in different countries such as in Australia, Europe, USA, Japan and Canada as Pradaxa [2,3]. Dabigatran helps in the prevention of heart strokes in patients accompanying atrial fibrillation [4]. The drug is more advantageous compared to warafin which also acts as one of the anticoagulant. Dabigatran is more efficient in preventing is chemic strokes and also plays a vital role in controlling the clinically significant bleeds [5,6]. The chemical name for dabigatran etexilate mesylate is β-alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]-phenyl]amino]methyl]-1methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinylethylester, methanesulfonate. The empirical formula is C 34 H 41 N 7 O 5 .CH 3 SO 3 H and the molecular weight is 723.86 g/mol. The drug structurally represented as below:
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.